Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Tanmay Bhamare

Pediatric Cardiology Little Rock, AR Medical Doctor

NPI 1083001382 CMS profile 2782284

4301 W Markham St # 753, Little Rock, AR 72205

Open in the dashboard

General payments

$981

10 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Tanmay Bhamare of Little Rock, AR is reported in the CMS Open Payments database as having received $981 across 10 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 68th percentile of Pediatric Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $412 3
2024 General $45 1
2023 General $109 2
2021 General $100 1
2019 General $315 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tanmay Bhamare
  • Pediatric Cardiology median
  • Middle half of Pediatric Cardiology
  • National median

In program year 2025, general payments to Tanmay Bhamare were reported at $412. Among 1,168 Pediatric Cardiology profiles paid that year, the median was $146 and the middle half received between $47 and $670.

Show as a table
Year Tanmay Bhamare Pediatric Cardiology median Middle half National median
2019 $315 $124 $35–$516 $163
2020 $0 $70 $23–$326 $114
2021 $100 $112 $27–$445 $132
2022 $0 $129 $36–$680 $149
2023 $109 $149 $38–$826 $160
2024 $45 $131 $37–$652 $164
2025 $412 $146 $47–$670 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Amgen Inc. $278 2 payments
  2. Impulse Dynamics (USA) Inc. $134 1 payment
  3. Gilead Sciences, Inc. $125 1 payment
  4. Merck Sharp & Dohme Corporation $100 1 payment
  5. Medtronic, Inc. $100 1 payment
  6. Genzyme Corporation $90 1 payment
  7. Edwards Lifesciences Corporation $86 1 payment
  8. Becton, Dickinson and Company $45 1 payment
  9. Abbott Laboratories $23 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $936 9 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $45 1 payment
Products named General payments · program years 2019–2025
  1. TAVNEOS $143 1 payment
  2. KRYSTEXXA $135 1 payment
  3. OPTIMIZER Cardiovascular Device $134 1 payment
  4. OPTIMIZER Cardiovascular Device $134 1 payment
  5. Biktarvy $125 1 payment
  6. STEGLATRO $100 1 payment
  7. Harmony $100 1 payment
  8. DISEASE STATE $90 1 payment
  9. SAPIEN 3 Ultra RESILIA $86 1 payment
  10. BD Introsyte $45 1 payment
  11. Other $23 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

483

Median for Cardiology: 2,533

Drug cost

$163,702

Median for Cardiology: $485,213

Branded share of claims

50.3%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Entresto Sacubitril/Valsartan Brand 56 $45,871
Jardiance Empagliflozin Brand 64 $44,284
Mounjaro Tirzepatide Brand 35 $36,736
Xarelto Rivaroxaban Brand 31 $17,607
Farxiga Dapagliflozin Propanediol Brand 20 $15,970
Eplerenone Generic 22 $899
Torsemide Generic 54 $791
Metoprolol Succinate Generic 50 $461
Spironolactone Generic 55 $438
Sotalol Sotalol Hcl Brand 24 $335

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 11 billing codes

Paid by Medicare

$8,169

Medicare's payments for the services billed

Medicare patients

75

Average age 42

Services billed

186

36 women, 39 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 48%
Heart failure 41%
Diabetes 21%
Atrial fibrillation 21%
Depression 17%
Arthritis 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

10 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Cardiology in Arkansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record